This application seeks renewed CCSG funding for the University of Virginia (UVA) Cancer Center, a matrix cancer center that brings together 132 Members from 23 Departments in the Schools of Medicine, Nursing, and Engineering, and in the College of Arts and Sciences. The UVA Cancer Center receives $19.85M from NCI, $48.62M from other peer-reviewed sources, and $8.72M from non-peer-reviewed sources, for a total of $77.19M in overall funding. Through faculty recruitment, re-organization, and robust infrastructure development, the UVA Cancer Center has continued to build on its exceptional basic-science foundations and has greatly enhanced its ability to accelerate clinical and translational cancer-focused research. Twenty-six new faculties have been recruited, including thirteen clinical investigators and/or physician-scientists and eight bioengineers, computational biologists, and/or molecular geneticists. To enhance trans-disciplinary and translational research and cancer focus, programs were consolidated so that all have basic science Members integrated with disease-focused and clinical or translational investigators. The Cancer Center has five Programs;Cancer Cell Signaling (SIG), Chemical and Structural Biology (CSB), Molecular Genetics and Epigenetics (GEN), Women's Oncology (WON), and Immunology/immunotherapy (IMM). The number of Full Members has been reduced by 30% and an Associate Member category has been created for investigators whose potential for peer-reviewed, cancer-focused research has yet to be actualized. This application requests support for eight Shared Resources: Advanced Microscopy, Biomolecular Analysis, Biorepository and Tissue Research, Flow Cytometry, Gene Targeting and Transgenic, Preclinical Tumor Analysis and Imaging, Biostatistics, and the Office for Clinical Research. A completely transformed infrastructure for translational and clinical research facilitates investigations using human tissues and the implementation of clinical trials. Major additions in research and clinical facilities strongly enhance the Cancer Center's ability to carry out its mission: New laboratory space covering 25,000 ft2houses IMM and WON Members, and a new cancer outpatient clinical building covering 151,000 ft2 will open in April 2011. Substantial activities have been initiated to reach underserved populations in minority groups and in Appalachia. This renewal application describes continued excellence in basic cancer research, enhanced cancer focus, and greatly strengthened clinical research leadership and infrastructure.

Public Health Relevance

The UVA Cancer Center's dual mission is to eliminate the threat of cancer, with skilled, compassionate care for the patients of today and with research and education for the patients of the future. Cancer Center Members draw on the deep resources of the University of Virginia to identify, analyze, and validate some of the most significant targets for cancer therapy, diagnosis and prevention, and to speed their translation to clinical application.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-23
Application #
8635284
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-09-16
Project End
2017-01-31
Budget Start
2014-03-14
Budget End
2015-01-31
Support Year
23
Fiscal Year
2014
Total Cost
$2,149,473
Indirect Cost
$789,047
Name
University of Virginia
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Meisner, Joshua K; Annex, Brian H; Price, Richard J (2015) Despite normal arteriogenic and angiogenic responses, hind limb perfusion recovery and necrotic and fibroadipose tissue clearance are impaired in matrix metalloproteinase 9-deficient mice. J Vasc Surg 61:1583-94.e1-10
Zarling, Angela L; Obeng, Rebecca C; Desch, A Nicole et al. (2014) MHC-restricted phosphopeptides from insulin receptor substrate-2 and CDC25b offer broad-based immunotherapeutic agents for cancer. Cancer Res 74:6784-95
Henretta, Melissa S; Copeland, Amy R; Kelley, Sarah L et al. (2014) Perceptions of obesity and cancer risk in female bariatric surgery candidates: highlighting the need for physician action for unsuspectingly obese and high risk patients. Gynecol Oncol 133:73-7
Jones, Ryan; Libby, Bruce; Showalter, Shayna L et al. (2014) Dosimetric comparison of (192)Ir high-dose-rate brachytherapy vs. 50 kV x-rays as techniques for breast intraoperative radiation therapy: conceptual development of image-guided intraoperative brachytherapy using a multilumen balloon applicator and in-room Brachytherapy 13:502-7
Santen, Richard J (2014) Menopausal hormone therapy and breast cancer. J Steroid Biochem Mol Biol 142:52-61
Wang, Shaolin; Yang, Zhongli; Ma, Jennie Z et al. (2014) Introduction to deep sequencing and its application to drug addiction research with a focus on rare variants. Mol Neurobiol 49:601-14
Cohen, Jarish N; Tewalt, Eric F; Rouhani, Sherin J et al. (2014) Tolerogenic properties of lymphatic endothelial cells are controlled by the lymph node microenvironment. PLoS One 9:e87740
Newhook, Timothy E; Blais, Edik M; Lindberg, James M et al. (2014) A thirteen-gene expression signature predicts survival of patients with pancreatic cancer and identifies new genes of interest. PLoS One 9:e105631
Hubbard, Matthew A; Khalil, Ashraf A; Schoeff, Stephen S et al. (2014) Nanoimmunoassay to Detect Responses in Head and Neck Cancer: Feasibility in a Mouse Model. Otolaryngol Head Neck Surg 151:92-99
Wang, Chun-Chao; Janes, Kevin A (2014) Non-genetic heterogeneity caused by differential single-cell adhesion. Cell Cycle 13:2149-50

Showing the most recent 10 out of 187 publications